Ku D D, Roberts R B, Sellers B M, Meezan E
Endocrinology. 1987 May;120(5):2166-73. doi: 10.1210/endo-120-5-2166.
The effect of insulin treatment on the renal hypertrophy and elevated renal Na+,K+-ATPase activity in rats with streptozotocin (STZ)-induced diabetes was examined. Rats with STZ-diabetes of 6- to 8-week duration had significantly lower body weights, higher plasma and urinary glucose concentrations, greater urinary volumes, increased kidney weights, and increased kidney/body weights and protein/kidney weight ratios compared to those in saline-citrate-injected controls. Specific Na+,K+-ATPase activity per mg protein in both cortical and outer medullary kidney homogenates was significantly elevated in diabetic vs. control animals, as was total renal Na+,K+-ATPase activity. One week of insulin treatment returned elevated plasma glucose, urinary volume, the protein/kidney weight ratio, and cortical and outer medullary Na+,K+-ATPase activity per mg protein to control values. Kidney weights and kidney/body weight ratios of diabetic animals remained elevated, as did absolute total renal Na+,K+-ATPase activity. After 3 weeks of insulin treatment, kidney weight and total renal Na+,K+-ATPase activity in diabetic animals returned to control values, but body weights remained lower than those in the controls, resulting in continued elevation of kidney/body weight ratios in the diabetic animals. The concurrent regression of both renal hypertrophy and elevated Na+,K+-ATPase activity to normal levels after insulin treatment of STZ-diabetic animals implicates renal growth rather than a direct effect of insulin as the primary factor controlling elevation and regression of Na+,K+-ATPase activity in the diabetic kidney. This finding demonstrates that the effect of renal hypertrophy can outweigh the intrinsic effects of insulin on an important renal transport system and that this effect may be as important as lack of hormone in determining the renal physiological responses in the disease. It is suggested that the increased renal tubular Na+,K+-ATPase activity is a key component of the renal hypertrophy and hyperfunction seen in diabetes.
研究了胰岛素治疗对链脲佐菌素(STZ)诱导的糖尿病大鼠肾肥大及肾Na⁺,K⁺-ATP酶活性升高的影响。与注射柠檬酸盐生理盐水的对照组相比,病程为6至8周的STZ糖尿病大鼠体重显著降低,血浆和尿葡萄糖浓度更高,尿量更大,肾重量增加,肾/体重及蛋白/肾重量比值升高。糖尿病动物皮质和外髓肾匀浆中每毫克蛋白的特异性Na⁺,K⁺-ATP酶活性及总肾Na⁺,K⁺-ATP酶活性均显著高于对照动物。胰岛素治疗1周后,升高的血糖、尿量、蛋白/肾重量比值以及皮质和外髓每毫克蛋白的Na⁺,K⁺-ATP酶活性恢复至对照值。糖尿病动物的肾重量和肾/体重比值仍升高,总肾Na⁺,K⁺-ATP酶活性绝对值也如此。胰岛素治疗3周后,糖尿病动物的肾重量和总肾Na⁺,K⁺-ATP酶活性恢复至对照值,但体重仍低于对照组,导致糖尿病动物的肾/体重比值持续升高。胰岛素治疗STZ糖尿病动物后,肾肥大和升高的Na⁺,K⁺-ATP酶活性同时恢复至正常水平,这表明肾生长而非胰岛素的直接作用是控制糖尿病肾中Na⁺,K⁺-ATP酶活性升高和恢复的主要因素。这一发现表明,肾肥大的影响可能超过胰岛素对重要肾转运系统的内在影响,并且这种影响在决定疾病中的肾生理反应方面可能与激素缺乏同样重要。提示肾小管Na⁺,K⁺-ATP酶活性增加是糖尿病中肾肥大和功能亢进的关键组成部分。